Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression - Top-Institutions - MDSpire

Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression

  • By

  • Giulia Lanzolla

  • Francesca Saba

  • Silvia Corrias

  • Filippo Lixi

  • Giulia Faa

  • Alessandro Colleo

  • Chiara Mura

  • Gian Luigi Canu

  • Federico Cappellacci

  • Alberto Cuccu

  • Giuseppe Giannaccare

  • Stefano Mariotti

  • Francesco Boi

  • February 2, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Moorfields Eye Hospital NHS Foundation Trust
    Moorfields Eye Hospital NHS Foundation Trust

    London, UK

    Key Differentiators

    • Ophthalmology
    • Endocrinology
    • Immunology

  • #2

    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH
    National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH

    Bethesda, MD

    Key Differentiators

    • Endocrinology
    • Immunology
    • Ophthalmology

  • #3

    University of Michigan Kellogg Eye Center
    University of Michigan Kellogg Eye Center

    Ann Arbor, MI

    Key Differentiators

    • Ophthalmology
    • Endocrinology

  • #4

    University of Pisa, Department of Clinical and Experimental Medicine
    University of Pisa, Department of Clinical and Experimental Medicine

    Pisa, Italy

    Key Differentiators

    • Endocrinology
    • Ophthalmology
    • Immunology

  • #5

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Endocrinology
    • Ophthalmology
    • Immunology

Original Source(s)

Subclinical ocular alterations in Graves' disease: The FUMO score, a new tool to predict Graves' orbitopathy progression

  • by Giulia Lanzolla, Francesca Saba, Silvia Corrias, Filippo Lixi, Giulia Faa, Alessandro Colleo, Chiara Mura, Gian Luigi Canu, Federico Cappellacci, Alberto Cuccu, Giuseppe Giannaccare, Stefano Mariotti, Francesco Boi

  • February 2, 2026

Related Content

AACE 2026: AI advances in thyroid care face barriers to adoption

Emerging tools show strong diagnostic potential—but validation, workflow integration, and reimbursement challenges remain.

A comprehensive review and meta-analysis of the association between thyroid disorders and the risk of liver cancer development

GLP-1 Drugs Linked to GI Effects, Uncertain Signals

Umbrella review evaluates over 1,700 trials to assess noncardiometabolic outcomes beyond weight and glycemic effects.